News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
US business grew by +12.8% YoY
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Marksans' OTC Famotidine Tablets USP are acid reducers
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Plans to double its manufacturing footprint to bolster the growth
Subscribe To Our Newsletter & Stay Updated
